Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Purlytin enters development for prostate cancer; another cancer indication abandoned

Sep. 8, 1998

FDA indicates approvability of DepoCyt for neoplastic meningitis from lymphomas

Sep. 7, 1998

Hyaluronic acid oligosaccharides inhibit tumor metastasis

Sep. 7, 1998

DW-2282: active enantiomer of DW-2143 and potent antitumor agent

Sep. 4, 1998

Label expansion recommended for Photofrin in U.S.

Sep. 4, 1998

Genetix awarded grant for antiangiogenic gene therapy development

Sep. 4, 1998

Clinical trials commence for Calydon's viral therapeutic for prostate cancer

Sep. 4, 1998

FDA approves Gemzar for first-line treatment of non-small cell lung cancer

Sep. 4, 1998

Coadministration of PNU-156765 and antiandrogen for prostate cancer

Sep. 4, 1998

A reduced deacetylated metabolite of FK-317 is responsible for antitumor activity

Sep. 4, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...